Igor Tsaur, Director and Chairman of the Department of Urology at the University Hospital Tübingen, shared a post on LinkedIn:
“We are changing the treatment landscape for a rare disease.
I am thrilled to share a major milestone for the DEPECA-1 trial (ClinicalTrials.gov ID NCT07110038): The first patient has officially started this promising treatment!
This Phase II study evaluates the combination of Enfortumab Vedotin and Avelumab as a first-line therapy for locally advanced inoperable and/or metastatic penile cancer – a field where new options are desperately needed.
Current Status:
- 4 out of 10 study centers are now initiated: University Hospitals of Tübingen, Mannheim, Mainz, and Rostock.
- Recruitment is gaining momentum.
This is a unique opportunity to shift the standard of care in a rare disease. If you are treating patients with advanced penile cancer, please consider a referral to one of our active study centers.
Let’s advance precision oncology together.”
More posts featuring Igor Tsaur.